2024
Long COVID-19 and Peripheral Serotonin: A Commentary and Reconsideration
Anderson G, Cook E, Blakely R, Sutcliffe J, Veenstra-VanderWeele J. Long COVID-19 and Peripheral Serotonin: A Commentary and Reconsideration. Journal Of Inflammation Research 2024, 17: 2169-2172. PMID: 38628604, PMCID: PMC11019386, DOI: 10.2147/jir.s456000.Peer-Reviewed Original ResearchPlatelet serotoninSerotonin valuesTrials of SSRIsSerotonin reuptake inhibitorsPlatelet serotonin transportersSerotonin reductionSSRI administrationSSRI treatmentReuptake inhibitorsSerotonin transporterMemory impairmentSerotonin levelsSSRIsSerotoninDepletion of plateletsPlasma serotoninPeripheral serotoninSequelae of COVID-19Viremia patientsCardiovascular sequelaeCirculating serotoninHyperaggregable stateTreatment of COVID-19Clinical trialsLong COVID
2022
Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter
Anderson G, Bruno-Pacella I. Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter. Psychopharmacology 2022, 240: 1-13. PMID: 36399187, DOI: 10.1007/s00213-022-06276-5.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsSerotonin transporterPlatelet serotonin transporterSERT occupancyReuptake inhibitorsSystematic reviewClinical implicationsPlatelet serotonin contentMeasurement of plateletPlatelet serotonin uptakePractical clinical implicationsStudy of plateletsSerotonin uptakeHealthy controlsSerotonin contentDifferent SSRIsClinical practicePlateletsInhibitorsUptakeSNRIsSSRIsPatientsReviewTransporters
2004
Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the rhesus monkey
Anderson GM, Barr CS, Lindell S, Durham AC, Shifrovich I, Higley JD. Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the rhesus monkey. Psychopharmacology 2004, 178: 339-346. PMID: 15452685, DOI: 10.1007/s00213-004-2011-7.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsCisternal cerebrospinal fluid (CSF) samplesPg/Young adult male rhesus monkeysRhesus monkeysSerotonin reuptake inhibitorsAdult male rhesus monkeysPlasma drug levelsCerebrospinal fluid samplesExtent of elevationMale rhesus monkeysTime courseNon-human primatesAutoreceptor desensitizationSerotonin neurochemistryReuptake inhibitorsNeurochemical effectsResponse latencyProlonged administrationDrug levelsDrug accumulationDay 0SertralineDiscontinuationBaseline
1998
Serotonin Transporter-Blocking Properties of Nefazodone Assessed by Measurement of Platelet Serotonin
Narayan M, Anderson G, Cellar J, Mallison R, Price L, Nelson J. Serotonin Transporter-Blocking Properties of Nefazodone Assessed by Measurement of Platelet Serotonin. Journal Of Clinical Psychopharmacology 1998, 18: 67-71.. PMID: 9472845, DOI: 10.1097/00004714-199802000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationBlood PlateletsCarrier ProteinsDepressive DisorderFemaleHumansMaleMembrane GlycoproteinsMembrane Transport ProteinsMiddle AgedNerve Tissue ProteinsPiperazinesSelective Serotonin Reuptake InhibitorsSerotoninSerotonin Plasma Membrane Transport ProteinsTriazolesConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsHAM-D scoresHamilton Rating ScaleSerotonin type 2Nefazodone treatmentPretreatment plateletBaseline plateletSSRI treatmentReuptake inhibitorsUptake blockadeTherapeutic dosesPlatelet serotoninClinical dosesDepressed patientsMajor depressionTreatment groupsDepression scoresNefazodoneType 2Percent changeUptake inhibitionRating ScalePercent decreasePlatelets